FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

OMB Number: 3235-0362											
Estimated average burden											
hours per response:	1.0										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol <u>Amylyx Pharmaceuticals, Inc.</u> [AMLX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
MILNE GEORGE M JR		X Director 10% Owner							
(Last) (First) (Middle) C/O AMYLYX PHARMACEUTICALS, INC.	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2022	Officer (give title Other (specify below) below)							
43 THORNDIKE STREET	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)		X Form filed by One Reporting Person							
CAMBRIDGE MA 02141	_	Form filed by More than One Reporting Person							
(City) (State) (Zip)									

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			or Disposed Of	5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		(Monulizayi real)	5)	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	(Instr. 4)	
Common Stock	01/06/2022		C4	689,425	A	(1)	910,821	D	
Common Stock	12/29/2022		G	13,800	D	\$0.00	897,021	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(13) [11] [11] [11] [11] [11] [11] [11] [11														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	n Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Preferred Stock	(1)	01/06/2022		4C		262,282	(1)	(1)	Common Stock	262,282	\$0.00	0	D	
Series B Preferred Stock	(1)	01/06/2022		4C		384,449	(1)	(1)	Common Stock	384,449	\$0.00	0	D	
Series C-1 Preferred Stock	(1)	01/06/2022		4C		19,482	(1)	(1)	Common Stock	19,482	\$0.00	0	D	
Series C-2 Preferred Stock	(1)	01/06/2022		4C		23,212	(1)	(1)	Common Stock	23,212	\$0.00	0	D	

Explanation of Responses:

1. Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Remarks:

SEC Form 5

[]

X

obligations may continue. See Instruction 1(b).

Form 4 Transactions Reported.

Form 3 Holdings Reported.

/s/ Joshua B. Cohen, as Attorney-in-Fact

02/14/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.